J&J Investigational NNRTI Shows Promise Against Resistant HIV
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase IIb data shows activity of TMC125 against NNRTI-resistant virus.
You may also be interested in...
J&J’s Prezista Approved For Treatment-Resistant HIV
The protease inhibitor – formerly known as TMC-114 – is to be co-administered with a low dose of ritonavir.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.